Virios Therapeutics, Inc. - VIRI STOCK NEWS

Virios Therapeutics, Inc. (NASDAQ: VIRI) announced a collaboration with the Bateman Horne Center to investigate combination antiviral therapy targeting Long COVID symptoms. This study will explore the efficacy of IMC-2, a combination of valacyclovir and celecoxib, on symptoms like fatigue and pain. Virios is providing an unrestricted grant for this investigator-sponsored study. With an estimated 30% of COVID-19 patients facing Long COVID, the research aims to provide crucial insights into potential treatments. Current antiviral candidate IMC-1 continues its Phase 2b clinical trials.

Virios Therapeutics (Nasdaq: VIRI) announced that CEO Greg Duncan will present at the H.C. Wainwright BioConnect Conference, occurring virtually from January 10-13, 2022. The presentation will discuss the impact of activated viruses on various chronic conditions, such as fibromyalgia and irritable bowel syndrome. Attendees can access the presentation on-demand starting January 10 at 7:00 AM ET via the company's website.

Virios is focused on developing antiviral therapies for chronic diseases, with its lead candidate IMC-1 showing promise in previous trials.

Virios Therapeutics, Inc. (NASDAQ: VIRI) announced significant progress in its Phase 2b FORTRESS trial for treating fibromyalgia, with over 50% of planned patients randomized. This trial follows the positive Phase 2a results, where 143 patients showed pain reduction with the novel antiviral therapy IMC-1, a combination of famciclovir and celecoxib. IMC-1 has received FDA's Fast Track designation, aiming to address the unmet needs of 10 million fibromyalgia patients in the U.S., many of whom currently rely on opioids for treatment.

Virios Therapeutics (NASDAQ: VIRI) announced significant developments in its Phase 2b fibromyalgia trial, with over 200 patients enrolled in the FORTRESS study. The company also filed an Investigational New Drug (IND) application with the FDA to investigate the use of IMC-1 for treating irritable bowel syndrome (IBS). Financially, Virios reported a net loss of $4.1 million for Q3 2021, with cash reserves of $19.2 million, sufficient to support operations into Q1 2023. The management plans a conference call on November 11, 2021, to discuss results and updates.

Virios Therapeutics (NASDAQ: VIRI) has announced it will report its third quarter 2021 financial results on November 11, 2021, before the market opens. A webcast and conference call will follow at 8:30 a.m. ET for a corporate update. The company is focused on innovative antiviral therapies targeting diseases like fibromyalgia. Its lead candidate, IMC-1, has shown promise in Phase 2a trials and is currently undergoing a Phase 2b trial named FORTRESS, which involves 460 patients and aims to pave the way for further registration studies.

Virios Therapeutics (Nasdaq: VIRI) has secured patent exclusivity for its valacyclovir-celecoxib combination drug until 2033, enhancing its intellectual property portfolio to 21 patents. The company’s lead candidate, IMC-1, targets fibromyalgia and is currently in a Phase 2b trial (FORTRESS) following promising Phase 2a results. Virios is also exploring new antiviral therapies as it aims to address chronic diseases linked to HSV-1 activation. The CEO expressed optimism about their expanding therapeutic focus.

Virios Therapeutics, Inc. (Nasdaq: VIRI) announced that CEO Greg Duncan will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will cover the impact of activated viruses on chronic diseases like fibromyalgia, IBS, and fatigue-related disorders. It will be available on-demand starting September 13, 2021, at 7:00 AM ET on the company's website. Virios’s lead candidate, IMC-1, aims to address these conditions and has shown promise in Phase 2 trials.

Virios Therapeutics, Inc. (Nasdaq: VIRI) announced the expansion of its social media platforms to engage with current and potential investors. The new channels on LinkedIn, Twitter, and Facebook will provide updates on the company’s activities and insights into chronic illnesses like fibromyalgia and HSV-1. Notably, all 41 sites in the ongoing Phase 2b clinical trial for fibromyalgia are fully activated and recruiting patients. CEO Greg Duncan highlighted the positive momentum from earlier studies showing the efficacy of IMC-1 in pain reduction, alongside its FDA fast track designation.

Virios Therapeutics (Nasdaq: VIRI) announced significant updates regarding its antiviral development strategies during a video interview with Stock News Now. CEO Greg Duncan discussed the ongoing Phase 2b trial for the company's lead candidate, IMC-1, which is targeting fibromyalgia. IMC-1, a combination of famciclovir and celecoxib, aims to suppress HSV-1 replication, with promising results from a previous Phase 2a trial. The company plans to expand its pipeline to include treatments for irritable bowel syndrome and fatigue-related disorders.